Skip to content
  • About us
    • About us
    • Executive commitee
    • Board of Directors
    • Scientific advisors
    • Corporate governance
    • ESG
  • myvac
    • myvac – individualized therapeutic vaccines
  • Pipeline
    • Pipeline
    • TG4050
    • TG4070
    • BT-001
    • TG6050
    • Publications and Presentations
    • Clinical trials FAQ
  • Investors
    • Investor Presentation & Contacts
    • Press releases & events
    • Financial Information
    • Stock Information
    • Annual General Meeting
  • Career
  • English
  • French
PHP Toggle Menu

Category: Press release

Transgene to Present Preclinical Data on Novel TG-MVA Prophylactic Vaccine Against mpox at the World Congress on Infectious Diseases

MPOX

Published 26 May 2026
Categorized as 2025, 2025, 2026, 2026, Press release

Transgene’s Combined General Meeting of May 22, 2026

AG 2026

Published 22 May 2026
Categorized as 2025, 2025, 2026, 2026, Press release

Availability of Preparatory Documents for the Combined General Meeting of May 22, 2026

AG 2026

Published 4 May 2026
Categorized as 2025, 2025, 2026, 2026, Press release

Transgene Provides Business and Financial Update for Q1 2026

Q1 2026

Published 29 April 2026
Categorized as 2025, 2025, 2026, 2026, Press release

Transgene Completes Patient Randomization in Phase 2 Part of Clinical Trial Evaluating TG4050 in the Adjuvant Treatment of Head and Neck Cancer

TG4050

Published 13 April 2026
Categorized as 2025, 2025, 2026, 2026, Myvac, Press release, TG4050

Transgene to Participate in Upcoming Investor Meetings

Investor meetings

Published 7 April 2026
Categorized as 2025, 2025, 2026, 2026, Press release

Transgene and NEC Bio Sign License Agreement to Prepare the Next Steps of the Development of TG4050 in Head and Neck Cancer

Licence Agreement

Published 2 April 2026
Categorized as 2025, 2026, Press release, TG4050

Transgene to Deliver an Oral Presentation on its Individualized Neoantigen Therapeutic Vaccine TG4050 at the World Vaccine Congress

WVC 2026

Published 26 March 2026
Categorized as 2026, Press release

Transgene Continues Progress to Reshape Early-Stage Cancer Treatment through Individualized Neoantigen Therapeutic Vaccines (INTV) Backed by Financial Visibility Until Early 2028

Business FYR 2025

Published 24 March 2026
Categorized as 2026, Press release

Transgene Announces Financial Calendar for 2026

financial calendar 2026

Published 4 February 2026
Categorized as 2025, 2026, Press release

Posts pagination

Newer posts Page 1 Page 2 … Page 33 Older posts
Get to know us

About us

myvac

Pipeline

Investors

Partnering

Company

Career

ESG

Suppliers

Contacts

Legal documents

Legal notices

Privacy Policy

Ethics and compliance

Cookie policy

  • About us
    • About us
    • Executive commitee
    • Board of Directors
    • Scientific advisors
    • Corporate governance
    • ESG
  • myvac
    • myvac – individualized therapeutic vaccines
  • Pipeline
    • Pipeline
    • TG4050
    • TG4070
    • BT-001
    • TG6050
    • Publications and Presentations
    • Clinical trials FAQ
  • Investors
    • Investor Presentation & Contacts
    • Press releases & events
    • Financial Information
    • Stock Information
    • Annual General Meeting
  • Career
  • English
  • French
Menu